UBS Securities LLC has recently announced that it has increased stake in AnPac Bio-Medical Science Co. Ltd. (NASDAQ:ANPC) by 127.05%. After grabbing 5095.0 shares, the institutional investor is now in possession of 2851.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.27% having worth around $23845.0. Moreover, Jane Street Capital LLC increased its share by 1961.0 to have a control over 2887.0 shares. And Two Sigma Securities LLC raised its holdings to 1327.0 shares by acquiring 1327.0 shares or 0.07% of the stake.
AnPac Bio-Medical Science Co. Ltd. (ANPC) concluded trading on 01/19/23 at a closing price of $10.17, with 0.18 million shares of worth about $1.85 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 72.90% during that period and on Thursday the price saw a gain of about 14.53%. Currently the company’s common shares owned by public are about 2.02M shares, out of which, 1.74M shares are available for trading.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 1 analysts are covering the ANPC stock and their offered price forecasts bring an average price target of $160.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $160.00 and could fall to a lowest price of $160.00. However, touching the estimated high of $160.00 would mean a gain of 93.64% for the stock.
The company recently came selling 1.0 shares which brought its stake up to 0.18% of the company’s outstanding shares.
AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) started trading at $9.49, above $0.61 from concluding price of the previous day. However, the stock later moved at a day high price of 11.99, or with a gain of 14.53%. Stock saw a price change of 64.03% in past 5 days and over the past one month there was a price change of 192.24%. Year-to-date (YTD), ANPC shares are showing a performance of 117.31% which decreased to -54.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.60 but also hit the highest price of $23.80 during that period. The average intraday trading volume for AnPac Bio-Medical Science Co. Ltd. shares is 39.32K. The stock is currently trading 94.96% above its 20-day simple moving average (SMA20), while that difference is up 133.62% for SMA50 and it goes to 96.63% higher than SMA200.
UBS Securities LLC acquired 5095.0 shares of AnPac Bio-Medical Science Co. Ltd. having value of about $23845.0. Data submitted at the U.S SEC by UBS Securities LLC revealed that the firm now holds 2851.0 shares in the company valued at close to $28994.67, or have control over 127.05% stake in the company. AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) currently have 2.02M outstanding shares and institutions hold larger chunk of about 1.90% of that. Holding of mutual funds in the company is about 0.18% while other institutional holders and individual stake holders have control over 0.94% and — of the stake respectively.
The stock has a current market capitalization of $20.53M. It has posted earnings per share of -$280.25 in the same period. It has Quick Ratio of 0.70. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ANPC, volatility over the week remained 19.70% while standing at 15.27% over the month.
Analysts are in expectations that AnPac Bio-Medical Science Co. Ltd. (ANPC) stock would likely to be making an EPS of $0 in the current quarter, while forecast for next quarter EPS is $0 and it is -$0.67 for next year. For the current quarter EPS, analysts have given the company a lowest target $0 which is $0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -21.30%.
Analysts at 1 brokerage firms have issued recommendations for the AnPac Bio-Medical Science Co. Ltd. (ANPC)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 1 Wall Street analysts, 1 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
